We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Study Has Mixed News on Safety of BI’s Pradaxa; Agency Makes No Labeling Changes
FDA Study Has Mixed News on Safety of BI’s Pradaxa; Agency Makes No Labeling Changes
An FDA study of postmarket reports shows that Boehringer Ingelheim’s blood thinner Pradaxa presents an increased risk of major gastrointestinal bleeding but a lower risk of strokes and deaths compared with warfarin.